Full Text Available

Note: Clicking the button above will open the full text document at the original institutional repository in a new window.

Semaglutide 2.4 mg for Obese Patients with MASH: A Cost-Effectiveness Analysis from the Italian NHS Perspective

Saved in:
Bibliographic Details
Published in:ClinicoEconomics and Outcomes Research
Format: Online Article RSS Article
Published: 2026
Subjects:
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1864030193420599298
collection WordPress RSS
FRELIP Feed Integration
container_title ClinicoEconomics and Outcomes Research
description
discipline_display Medical & Health Sciences
discipline_facet Medical & Health Sciences
format Online Article
RSS Article
genre Journal Article
id rss_article:47475
institution FRELIP
journal_source_facet ClinicoEconomics and Outcomes Research
publishDate 2026
publishDateSort 2026
record_format rss_article
spellingShingle Semaglutide 2.4 mg for Obese Patients with MASH: A Cost-Effectiveness Analysis from the Italian NHS Perspective
— — — — — Health and Safety
Public Health
Medical & Health Sciences
sub_discipline_display Public Health
sub_discipline_facet Public Health
subject_display — — — — — Health and Safety
Public Health
Medical & Health Sciences
— — — — — Health and Safety
Public Health
Medical & Health Sciences
subject_facet — — — — — Health and Safety
Public Health
Medical & Health Sciences
title Semaglutide 2.4 mg for Obese Patients with MASH: A Cost-Effectiveness Analysis from the Italian NHS Perspective
title_auth Semaglutide 2.4 mg for Obese Patients with MASH: A Cost-Effectiveness Analysis from the Italian NHS Perspective
title_full Semaglutide 2.4 mg for Obese Patients with MASH: A Cost-Effectiveness Analysis from the Italian NHS Perspective
title_fullStr Semaglutide 2.4 mg for Obese Patients with MASH: A Cost-Effectiveness Analysis from the Italian NHS Perspective
title_full_unstemmed Semaglutide 2.4 mg for Obese Patients with MASH: A Cost-Effectiveness Analysis from the Italian NHS Perspective
title_short Semaglutide 2.4 mg for Obese Patients with MASH: A Cost-Effectiveness Analysis from the Italian NHS Perspective
title_sort semaglutide 2.4 mg for obese patients with mash: a cost-effectiveness analysis from the italian nhs perspective
topic — — — — — Health and Safety
Public Health
Medical & Health Sciences
url https://www.dovepress.com/semaglutide-24-mg-for-obese-patients-with-mash-a-cost-effectiveness-an-peer-reviewed-fulltext-article-CEOR